Literature DB >> 9600327

Proteasome is a carrier to translocate doxorubicin from cytoplasm into nucleus.

K Kiyomiya1, S Matsuo, M Kurebe.   

Abstract

When an effective concentration of doxorubicin (DXR) was added into L1210 of a mouse leukemia cell line, DXR was rapidly distributed much more in the nuclei than in the other organelle within a few minutes. A [14C]DXR-binding fraction was obtained from the cytosol prepared from L1210 cells. The fraction was adsorbed to hydroxylapatite matrix and eluted from the matrix by 50-150 mM potassium phosphate buffer. The fraction showed high DXR-binding and Suc-Leu-Leu-Val-Tyr-MCA-degrading activity. The binding of [14C]DXR was inhibited by unlabeled DXR. Gel chromatography of the fraction with Sephacryl S-300 separated two fractions of high molecular weight (Peak I, approx. 750 kDa) and low molecular weight (Peak II). Peak I showed proteolytic activity. [14C]DXR-binding Peak I had much higher affinity to DNA-cellulose than [14C]DXR-binding Peak II. [14C]DXR-Peak I complex also was retained into the nuclei isolated from L1210 cells, temperature-dependently. These results suggest that a specific carrier to translocate DXR from cytoplasm into nucleus exists in L1210 cell and the carrier is proteasome.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9600327     DOI: 10.1016/s0024-3205(98)00151-9

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  15 in total

1.  Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.

Authors:  William Guerrant; Vishal Patil; Joshua C Canzoneri; Adegboyega K Oyelere
Journal:  J Med Chem       Date:  2012-02-13       Impact factor: 7.446

2.  Effect of ubiquitination on peptidase activities of proteasomes in genotoxic stress.

Authors:  T N Moiseeva; O A Fedorova; A S Tsimokha; A G Mittenberg; N A Barlev
Journal:  Dokl Biochem Biophys       Date:  2010-12-24       Impact factor: 0.788

3.  Intracellular trafficking of a pH-responsive drug metal complex.

Authors:  Azadeh Kheirolomoom; Elizabeth S Ingham; Joel Commisso; Neveen Abushaban; Katherine W Ferrara
Journal:  J Control Release       Date:  2016-10-13       Impact factor: 9.776

Review 4.  The ubiquitin-proteasome system as a drug target in cerebrovascular disease: therapeutic potential of proteasome inhibitors.

Authors:  Mario Di Napoli; BethAnn McLaughlin
Journal:  Curr Opin Investig Drugs       Date:  2005-07

5.  Cardiac systolic dysfunction in doxorubicin-challenged rats is associated with upregulation of MuRF2 and MuRF3 E3 ligases.

Authors:  Marcia Gracindo da Silva; Elisabete Mattos; Juliana Camacho-Pereira; Tatiana Domitrovic; Antonio Galina; Mauro W Costa; Eleonora Kurtenbach
Journal:  Exp Clin Cardiol       Date:  2012-09

Review 6.  Activation of the ubiquitin-proteasome system in doxorubicin cardiomyopathy.

Authors:  Mark J Ranek; Xuejun Wang
Journal:  Curr Hypertens Rep       Date:  2009-12       Impact factor: 5.369

7.  Distinct classes of proteasome-modulating agents cooperatively augment recombinant adeno-associated virus type 2 and type 5-mediated transduction from the apical surfaces of human airway epithelia.

Authors:  Ziying Yan; Roman Zak; Yulong Zhang; Wei Ding; Simon Godwin; Keith Munson; Richard Peluso; John F Engelhardt
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

8.  A therapeutic dose of doxorubicin activates ubiquitin-proteasome system-mediated proteolysis by acting on both the ubiquitination apparatus and proteasome.

Authors:  Jinbao Liu; Hanqiao Zheng; Mingxin Tang; Youn-Chul Ryu; Xuejun Wang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-10-31       Impact factor: 4.733

Review 9.  Rise of cyborg microrobot: different story for different configuration.

Authors:  Fanan Wei; Chao Yin; Jianghong Zheng; Ziheng Zhan; Ligang Yao
Journal:  IET Nanobiotechnol       Date:  2019-09       Impact factor: 1.847

10.  Anthracyclines, proteasome activity and multi-drug-resistance.

Authors:  Mirela R Fekete; William H McBride; Frank Pajonk
Journal:  BMC Cancer       Date:  2005-09-13       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.